Since 1998, Mr. Schmertzler has served as a Lecturer and Adjunct Professor at Yale University in the Department of Economics and School of Management. From 2018 to 2025, he also served as a Visiting Professor at Yale-NUS College Singapore. Mr. Schmertzler currently serves as director and Chairman of PTC Therapeutics, Inc. (Nasdaq: PTCT), a publicly traded biotechnology company that develops treatments for rare genetic disorders. He is also currently Chairman and a director of Berryville Holdings, a company focused on attribution and protection systems for the defense and intelligence community; Dispel, LLC, a company that builds communication networks for operational technology; and SHY Therapeutics, a biotechnology company developing cancer and infectious disease therapeutics, where he serves as Executive Chairman. He is also a director of AgNovos, a biotechnology company developing osteoporosis therapeutics. In addition, Mr. Schmertzler currently serves as a Charter Trustee of Phillips Academy Andover. Mr. Schmertzler s prior investment and corporate finance experience includes serving, from 2012 to 2020, as a post-bankruptcy independent director of Lehman Commercial Paper, Inc., the largest post-bankruptcy Lehman subsidiary. Earlier in his career, from 1997 to 2014, Mr. Schmertzler was a Managing Director at Credit Suisse First Boston Equity Partners, L.P., serving in various roles including as Chair of the Investment Committee. Prior to that, he served as a Managing Director of Morgan Stanley and held senior roles including as President of Morgan Stanley Leveraged Capital Funds, founder of its biotechnology investment banking group, head of its insurance industry investment banking group, and a Managing Director in its Mergers and Acquisitions department. Prior to 1985, he also held senior roles at Shearson Lehman Brothers Inc. where he headed its international investment banking businesses and Lehman Brothers Kuhn Loeb Inc. where he served as Chief Financial Officer and as an investment banker. He received a B.A. from Yale College in Molecular Biophysics and Biochemistry, History, and City Planning, and an M.B.A. from Harvard Business School. Mr. Schmertzler s extensive experience in private equity, investment banking, corporate finance, biotechnology and cybertechnology, and service in senior governance roles of multiple public and private organizations, brings valuable investment, operating, finance, cybertechnology and governance knowledge and insights to the board of directors.